0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Severe Livedoid Vasculopathy Associated With Antiphosphatidylserine-Prothrombin Complex Antibody Successfully Treated With Warfarin

Shinji Noda, MD; Yoshihide Asano, MD, PhD; Masahide Yamazaki, MD, PhD; Yohei Ichimura, MD; Zenshiro Tamaki, MD, PhD; Tomonori Takekoshi, MD, PhD; Makoto Sugaya, MD, PhD; Shinichi Sato, MD, PhD
Arch Dermatol. 2011;147(5):621-623. doi:10.1001/archdermatol.2011.106.
Text Size: A A A
Published online

Extract

Livedoid vasculopathy (LV) is a chronic recurrent skin disease associated with various coagulopathies, clinically characterized by livedo reticularis, atrophie blanche, and painful ulcerations predominantly localized on the lower extremities. We herein report dramatic effects of warfarin therapy against rapidly progressive digital gangrene and foot ulcers in a patient with LV and antiphosphatidylserine-prothrombin complex antibody (aPS/PT).

Browning  CECallen  JP Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006;142 (1) 75- 78
PubMed Link to Article[[XSLOpenURL/10.1001/archderm.142.1.75]]
Deng  AGocke  CDHess  JHeyman  MPaltiel  MGaspari  A Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006;142 (11) 1466- 1469
PubMed Link to Article[[XSLOpenURL/10.1001/archderm.142.11.1466]]
Di Giacomo  TBHussein  TPSouza  DGCriado  PR Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs—a prospective study. J Eur Acad Dermatol Venereol 2010;24 (11) 1340- 1346
PubMed Link to Article[[XSLOpenURL/10.1111/jdv.2010.24.issue-11]]
Miyakis  SLockshin  MDAtsumi  T  et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4 (2) 295- 306
PubMed Link to Article[[XSLOpenURL/10.1111/jth.2006.4.issue-2]]
Atsumi  TAmengual  OYasuda  SKoike  T Antiprothrombin antibodies—are they worth assaying? Thromb Res 2004;114 (5-6) 533- 538
PubMed Link to Article[[XSLOpenURL/10.1016/j.thromres.2004.08.024]]
Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.

Clinical photographs of the study patient. A, Gangrene of the right fourth and fifth toes and ulcerations on the right dorsal foot at the initial presentation. B, Ulcerations on the right lateral malleolus. C, Porcelain-white scarring and surrounding hyperpigmentation on the lower legs and dorsal feet. D, After 3 weeks of treatment, gangrene extends to all the right toes, and the ulcer is expanded. E, One year after the initiation of warfarin therapy, necrotic toes amputated spontaneously, and the size of the ulcer is significantly reduced. F, Ulcerations on the right lateral malleolus are healed.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Skin biopsy specimen from the ulcer edge shows acanthosis, perivascular lymphoneutrophilic infiltration, capillary proliferation in the papillary dermis, and dermal fibrosis. No occluded vessels or fibrinoid degeneration were found (hematoxylin-eosin, original magnification ×100).

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 2

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario

brightcove.createExperiences();